Csl Ltd has released a press release.
2016 FY Results Announcements and Analysts Briefing
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CSL
- AFSTYLA (rFVIII-Single Chain) FDA approval
- Flucelvax Quadrivalent (Influenza Vaccine) - FDA Approval
- IDELVION(R) (rFIX-FP) - European Commission Approval
- CSL to acquire Novartis influenza vaccine business
- Chairman`s Address to Shareholders
Later from CSL
- FDA Accepts BLA for Hereditary Angioedema Therapy
- Afstyla CHMP Recommendation
- Positive Results from CSL112 Phase 2b Trial
- AFSTYLA (rFVIII-Single Chain) European Commission Approval
- FY2017 Profit Upgrade
Follow CSL into a list and get an email when it puts out news.
Follow CSL